Pfizer Inc.
HealthcareNYSE:PFE · New York Stock Exchange
+$0.00 today
Vol 19.56M · Avg 36.50M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $1.7B |
| Short-term Investments | $11.4B |
| Receivables | $12.6B |
| Inventory | $10.7B |
| Other Current | $6.5B |
| Total Current Assets | $42.8B |
| PP&E (Net) | $19.4B |
| Goodwill | $71.4B |
| Intangible Assets | $52.6B |
| Long-term Investments | $1.6B |
| Tax Assets | $10.0B |
| Other Non-current | $9.8B |
| Total Non-current Assets | $164.8B |
| Total Assets | $207.6B |
Analysis
Selected assets total $207.6B for Latest. The largest visible component is Goodwill at $71.4B, about 34.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.1B +9.5% | $1.0B -63.4% | $2.9B +585.8% | $416.0M -78.6% | $1.9B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $12.5B -35.9% | $19.4B +97.6% | $9.8B -55.9% | $22.3B -23.4% | $29.1B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $11.9B -19.6% | $14.8B -4.9% | $15.5B +7.0% | $14.5B -7.7% | $15.7B | $533.8M | $399.4M | -$1.7B |
| Inventory | $10.7B -1.8% | $10.9B +6.5% | $10.2B +13.5% | $9.0B -0.9% | $9.1B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $6.8B +59.3% | $4.3B -13.4% | $4.9B -2.1% | $5.0B +31.3% | $3.8B | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $42.9B -14.8% | $50.4B +16.2% | $43.3B -15.5% | $51.3B -14.1% | $59.7B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $21.5B +17.1% | $18.4B -2.9% | $18.9B +16.4% | $16.3B +9.4% | $14.9B | $1.2B | $1.5B | $687.8M |
| Goodwill | $71.3B +4.0% | $68.5B +1.1% | $67.8B +31.9% | $51.4B +4.4% | $49.2B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $53.7B -3.0% | $55.4B -14.6% | $64.9B +49.6% | $43.4B +72.5% | $25.1B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $1.7B -22.0% | $2.2B -85.5% | $15.4B +2.0% | $15.1B -30.0% | $21.5B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $9.7B +12.0% | $8.7B +133.7% | $3.7B -44.6% | $6.7B +100.3% | $3.3B | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $7.3B -25.6% | $9.8B -21.3% | $12.5B -5.3% | $13.2B +71.4% | $7.7B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $165.3B +1.4% | $163.0B -11.0% | $183.2B +25.5% | $145.9B +19.8% | $121.8B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $208.2B -2.5% | $213.4B -5.8% | $226.5B +14.9% | $197.2B +8.7% | $181.5B | $13.3B | $11.9B | $10.6B |
| Account Payables | $5.2B -7.0% | $5.6B -16.1% | $6.7B -1.5% | $6.8B +22.1% | $5.6B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $3.5B -49.8% | $6.9B -32.9% | $10.3B +252.6% | $2.9B +30.9% | $2.2B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $2.3B +48.0% | $1.6B +25.4% | $1.3B | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $784.0M -48.1% | $1.5B -44.0% | $2.7B +7.1% | $2.5B -17.8% | $3.1B | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $18.3B -21.0% | $23.2B -0.5% | $23.3B -10.3% | $26.0B -8.1% | $28.3B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $37.0B -14.0% | $43.0B -10.0% | $47.8B +13.4% | $42.1B -1.2% | $42.7B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $61.6B +7.4% | $57.4B -5.1% | $60.5B +89.5% | $31.9B -8.1% | $34.8B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $2.4B +13.1% | $2.1B +231.6% | $640.0M -37.4% | $1.0B +193.1% | $349.0M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $18.1B -10.1% | $20.1B -29.0% | $28.3B +7.9% | $26.2B -0.1% | $26.2B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $84.4B +3.0% | $81.9B -8.4% | $89.4B +51.2% | $59.2B -3.6% | $61.3B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $121.4B -2.8% | $124.9B -9.0% | $137.2B +35.5% | $101.3B -2.6% | $104.0B | $14.7B | $3.7B | $9.6B |
| Common Stock | $481.0M +0.2% | $480.0M +0.4% | $478.0M +0.4% | $476.0M +0.6% | $473.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $114.6B -1.8% | $116.7B -1.4% | $118.4B -5.8% | $125.7B +21.5% | $103.4B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$8.1B -2.9% | -$7.8B +1.5% | -$8.0B +4.1% | -$8.3B -40.8% | -$5.9B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $299.0M +1.7% | $294.0M +7.3% | $274.0M +7.0% | $256.0M -2.3% | $262.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $86.8B -1.9% | $88.5B -0.9% | $89.3B -6.9% | $95.9B +23.8% | $77.5B | $9.1B | $7.7B | $3.3B |
| Total Debt | $67.4B +0.6% | $67.0B -5.4% | $70.8B +103.2% | $34.9B -5.8% | $37.0B | $724.2M | $410.6M | $399.4M |
| Net Debt | $66.3B +0.5% | $66.0B -3.0% | $68.0B +97.4% | $34.4B -1.7% | $35.1B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.05B
Novo Nordisk A/S
NYSE:NVO
$196.75B
Amgen Inc.
NASDAQ:AMGN
$190.64B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.38B
Danaher Corporation
NYSE:DHR
$127.48B
Stryker Corporation
NYSE:SYK
$120.34B
Bristol-Myers Squibb Company
NYSE:BMY
$116.57B
GSK plc
NYSE:GSK
$106.57B
Sanofi
NASDAQ:SNY
$106.47B
Boston Scientific Corporation
NYSE:BSX
$69.91B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does PFE have?
Pfizer Inc. (PFE) reported $1.14B in cash and equivalents in fiscal 2025.
How much debt does PFE carry?
Pfizer Inc. (PFE) reported $67.42B of total debt, with net debt of $66.27B.
Explore More
Continue the stock analysis
Jump to another research area for this company.